Inclusion Criteria:

          -  Histologically or cytologically confirmed pancreatic adenocarcinoma with metastasis

          -  Must be off their prior cytotoxic regimen a minimum of two weeks but no more than four
             weeks from initiating trial treatment.

        Measurable disease by RECIST 1.1.

        Demonstrate adequate organ function

        Normal Vitamin D level.

        Able to submit an archival tumor specimen (primary or metastatic site). Patients with
        cytology only that do not have adequate archived tumor specimen available, will require a
        baseline biopsy.

        Exclusion Criteria:

          -  Is currently participating and receiving trial therapy or has participated in a trial
             of an investigational agent and received trial therapy or used an investigational
             device within 3 weeks of the first dose of trial treatment.

          -  Hypersensitivity to cabiralizumab, nivolumab, or gemcitabine or any of its excipients.

          -  Previous malignancies (except non-melanoma skin cancers, and in situ bladder, gastric,
             colorectal, endometrial, cervical/dysplasia, melanoma, or breast cancers) unless
             complete remission was achieved at least 2 years prior to study entry and no
             additional therapy is required during the study period.

          -  Evidence of central nervous system (CNS) metastasis

          -  Participants with active, known, or suspected autoimmune disease.

          -  Current or history of clinically significant muscle disorders (e.g., myositis), recent
             unresolved muscle injury, or any condition known to elevate serum CK levels.

          -  Uncontrolled or significant cardiovascular disease

          -  Prior organ allograft or allogeneic bone marrow transplantation.

          -  Any uncontrolled inflammatory GI disease including Crohn's Disease and ulcerative
             colitis.

          -  Evidence of coagulopathy or bleeding diathesis.

          -  Has received prior therapy with a CSF-1R pathway inhibitors, anti-PD-1, anti-PD-L1,
             anti PD-L2, anti-CTLA-4.